Oruka Therapeutics, Inc. (ORKA)
| Market Cap | 3.47B +1,190.8% |
| Revenue (ttm) | n/a |
| Net Income | -84.31M |
| EPS | -1.85 |
| Shares Out | 50.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,091,939 |
| Open | 67.84 |
| Previous Close | 67.74 |
| Day's Range | 66.51 - 69.17 |
| 52-Week Range | 8.91 - 71.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 73.33 (+6.23%) |
| Earnings Date | May 13, 2026 |
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price target is $73.33, which is an increase of 6.23% from the latest price.
News
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standa...
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026
Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Ultra-long acting antibodies targeting IL-23p19 and IL-17AF aim to transform psoriatic disease care with annual or semi-annual dosing, high efficacy, and potential off-treatment remission. Key Phase II data for ORKA-001 is expected in the second half of the year.
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing two long-acting monoclonal antibodies for psoriatic disease, aiming for annual or biannual dosing and potential off-treatment remission. Key phase II data are expected in 2024–2025, with a strong financial position and innovative trial designs supporting differentiation from current standards.
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for OR...
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission
Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference
Two lead monoclonal antibody programs are advancing in psoriatic disease, targeting once or twice-yearly dosing and aiming for high efficacy and durable remission. Key phase II and I data readouts are expected through 2027, supported by a strong cash position.
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics Announces $180 Million Private Placement
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new stan...
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-t...
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 ...
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard...
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to...
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation ...
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standa...
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides...
Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
Oruka is advancing biologics for psoriatic disease with ultra-long dosing intervals and aims for multi-year remission, leveraging strong clinical design and a robust cash position. Sequential and combination regimens with ORKA-001 and ORKA-002 target best-in-class efficacy and safety.
Oruka Therapeutics to Present at Multiple March Investor Conferences
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standar...
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial effic...